Dr. Holland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
580 S Loop Rd
Ste 200
Edgewood, KY 41017Phone+1 513-569-3741Fax+1 513-569-3941
Education & Training
- National Capital ConsortiumResidency, Ophthalmology, 1986 - 1987
- University of Iowa Hospitals and ClinicsResidency, Ophthalmology, 1985 - 1986
- University of MinnesotaResidency, Ophthalmology, 1982 - 1985
- Henry Ford Health/Henry Ford HospitalInternship, Transitional Year, 1981 - 1982
- Loyola University Chicago Stritch School of MedicineClass of 1981
Certifications & Licensure
- CA State Medical License 2007 - Present
- OH State Medical License 1999 - 2026
- KY State Medical License 2000 - 2025
- MN State Medical License 1987 - 2007
- IA State Medical License 1985 - 1988
- MI State Medical License Active through 1982
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Cornea Donor Study Start of enrollment: 2000 Jan 10
- Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Start of enrollment: 2009 Mar 01
- A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery Start of enrollment: 2010 May 01
- Join now to see all
Publications & Presentations
PubMed
- Donor Tissue Preservation Time Impact on Keratolimbal Allograft Outcomes.Robert J Porter, Daniel Peretz, Waleed K Alsarhani, Clara C Chan, Albert Y Cheung
Cornea. 2024-10-29 - Reply.Edward J Holland, Albert Y Cheung, Ali R Djalilian
Cornea. 2024-02-01 - 5 citationsPhase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).Pedram Hamrah, Mina Massaro-Giordano, David Schanzlin, Edward Holland, Gregg Berdy
Ophthalmology and Therapy. 2024-02-01
Press Mentions
- Elite Stem-Cell Transplant Program for Eye Surface Damage Opens at UCI HealthFebruary 1st, 2023
- Cracking the Cornea ConundrumSeptember 2nd, 2022
- Masters of the OphthoverseAugust 4th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: